trial

A Pilot Trial of Curcumin Effects on Cognition in Schizophrenia

NCTId NCT02476708
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Terminated
Enrollment 12 (actual)
Sponsored by Yale University
Primary completion 2017-08-24
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Terminated
Enrollment
12 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2016-02-11
Primary completion
2017-08-24
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
curcumin 1800mg

Sponsors

Yale UniversityLead Sponsor

Investigators

1
Cenk Tek, MDPrincipal Investigator

Sites

1 total
New Haven, United States

Facts & assertions

4 sourced
Enrollment
12
Phase
NA
Primary Completion Date
2017-08-24
Status
TERMINATED
relationships
The graph out of here
drug
curcumin 1800mg
drug
lead_sponsor
Yale University
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Cenk Tek, MD
person